



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/698,881 | 10/31/2003 | Thomas R. Skwarek | P-11670.00 | 2004 |

27581 7590 05/21/2007
MEDTRONIC, INC.
710 MEDTRONIC PARKWAY NE
MINNEAPOLIS, MN 55432-9924

| |
|----------|
| EXAMINER |
|----------|

FLORY, CHRISTOPHER A

| | |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

3762

| | |
|-----------|---------------|
| MAIL DATE | DELIVERY MODE |
|-----------|---------------|

05/21/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/698,881

Applicant(s)

SKWAREK ET AL.

Examiner

Christopher A. Flory

Art Unit

3762

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 27 December 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,2,4-11,18-22,24,25 and 27-39 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,2,4-11,18-22,24,25 and 27-39 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date: _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>10/19/2006</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION***Double Patenting***

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Art Unit: 3762

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. **Claims 1, 3, 5-11, 18, 24, 26, 30, 32, and 38 stand provisionally rejected on the ground of nonstatutory obviousness-type double patenting** as being unpatentable over claims 1-4, 7-11, 14-16, 22-28, 33-37, 40, 53, 56-58, 61-62, 65-67, 70-73, 78-82, 85-89, and 99-102 of copending Application No. 10/441,784. Although the conflicting claims are not identical, they are not patentably distinct from each other because both applications disclose a method and device with one or more leads for the delivery of one or more therapeutic stimulation pulses or sequences to tissue via an implantable medical device for the purpose of treating sexual dysfunction, where the stimuli might be delivered in response to telemetry signals from a patient programmer or in response to a sensed physiological signal, and might also be delivered in conjunction with a drug.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

3. **It is noted that this is already a formal application of the double patenting rejection, and Applicant should address the issue in the next reply to this Office Action.**

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

5. **Claims 30-32 and 38-39 stand rejected under 35 U.S.C. 102(b) as being anticipated by Krakovsky et al. (US Patent 5,454,840, hereinafter referred to as Krakovsky'840).**

Regarding claims 30-32 and 38-39, Krakovsky'840 discloses an implantable medical device (potency package 30) comprising one or more leads (Fig. 10, leads 48 and 49), a pulse generator (46), an optional agent pump (the implantable drug pump consisting of chamber 60, pump 62, and delivery tube 64) and a processor (42) to control the therapy delivery circuit; wherein the device is capable of delivering stimulation pulses and agents in a complimentary fashion causing the fiber structure of the prostate gland to relax, given these programmed parameters.

It is noted that the functional language of the device claims does not distinguish the instant application over the Krakovsky'840 device because the earlier patented device is inherently capable of all the limitations contained in the instant claims.

Claim Rejections - 35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

8. **Claims 1, 2, 5-11 and 18 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Krakovsky'840 in view of Whitehurst'294.**

Regarding claims 1, 2, 5-10 and 18, Krakovsky'840 discloses the method substantially as claimed, including delivering one or more therapeutic stimulation pulses (Fig. 11) via an implantable medical device (potency package 30) to treat sexual dysfunction in which the stimulation can cause an erection and either cause (Fig. 13) or prevent (Fig. 12) ejaculation (column 1, lines 42-53) or premature ejaculation (column 5, lines 32-33); the stimulation being delivered in response to telemetry signals from a patient programmer (column 1, lines 36-38, 44-45), the second pulse train including more pulses per unit time (is of higher frequency) than the first pulse train (Figs. 12-13);

Art Unit: 3762

the disclosed method also comprising delivering drugs to the prostate in conjunction with delivering electrical stimulation pulses (column 4, lines 28-54). Krakovsky'840 does not disclose that the stimulation pulses are delivered directly to the tissue of the prostate. However, in the same field of endeavor, Whitehurst'294 teaches direct electrical stimulation of the prostate to provide a minimally invasive means of reducing prostate volume (column 3, lines 55-68). Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the method of Krakovsky'840 to include direct electrical stimulation of the prostate gland as taught by Whitehurst'294 in order to provide the same benefit of reducing prostate volume with a minimally invasive process (motivation to combine provided by Whitehurst'294, column 3, lines 55-68).

Regarding claim 11, Krakovsky'840 discloses the method of the instant application substantially as claimed except that the therapeutic stimulation pulses may be delivered in response to a sensed physiological condition. Whitehurst'294 teaches sensing necrosis, volume or inflammation of tissue as well as hormone, enzyme, or drug levels and changes as a means to determine the strength, duration, and pattern of electrical stimulation required to produce the desired treatment effect (column 11, lines 35-59).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to incorporate a sensor for sensing physiological conditions into the device and method of the Krakovsky et al. patent for the same advantage of an alternate or more accurate means for determining the proper therapy levels to be

delivered to the patient (motivation to combine provided by Krakovsky et al., column 11, lines 35-59).

9. Claims 19-22 and 33-37 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Krakovsky'840 in view of Whitehurst'294, and further in view of Mann et al. (US Patent 6,941,171, hereinafter referred to as Mann'171).

Krakovsky'840 in view of Whitehurst'294 discloses the method of the instant application substantially as claimed except that the therapeutic stimulation pulses be used to train the prostate gland to become more compliant, i.e. relax its fiber structure. In the same field of endeavor, Mann'171 teaches a stimulation of the nerve pathways of the bladder that yields the desired result of diminishing involuntary bladder contractions (i.e. relaxing the fibrous muscle structure of the bladder) and increasing volume of the bladder (i.e. increasing compliance of the bladder wall) (ABSTRACT).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention that similar stimulation of the prostate, given its similar physical composition to the bladder and its corollary position in the reproductive system to that of the bladder in the urinary system, could be employed in the method of the Krakovsky'840 patent to achieve the same results of a relaxing of the fiber structure and increase in compliance of the prostate organ (motivation to combine provided by Mann'171, ABSTRACT).

See Figs. 12 and 13 of Krakovsky'840 regarding claims 34-37.

Further, Krakovsky'840 does not disclose that the time periods for the first and second pulse trains are on an order of a week. However, it would have been obvious to

Art Unit: 3762

one of ordinary skill in the art at the time of the invention to use a training period on the order of a week, since it has been held that, where the general conditions of a claim are disclosed in the prior art, discovering an optimum value or range for a result effective variable involves only routine skill in the art.

10. Claims 4 and 21 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Krakovsky'840 in view of Whitehurst'294 as applied to claims 1 and 19 above, and further in view of Mann'171.

Krakovsky'840 discloses the method of the instant application substantially as claimed except for the parameter limitations of using pulse widths between 180 and 450 microseconds and frequencies between 50 and 100 Hz (claim 4) or 2 and 20 Hz (claim 21). In the same field of endeavor, Mann'171 teaches a pulse width range of 50-350 microseconds and a frequency range of 2-20 pulses per second (Hz) as being typical for electrical stimulation of male reproductive nerves (column 21, line 48 through column 22, line 14).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to employ these ranges for stimulation parameters in the method of the Krakovsky'840 to achieve the same advantage of successful and clinically safe control of male sexual function (motivation to combine provided by Mann'171, column 21, line 48 through column 22, line 14).

11. Claims 24, 25 and 27-29 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Krakovsky'840.

Regarding claims 24, 25 and 27-29, Krakovsky'840 discloses an implantable medical device (potency package 30) comprising one or more leads (Fig. 10, leads 48 and 49), a pulse generator (46), an optional agent pump (the implantable drug pump consisting of chamber 60, pump 62, and delivery tube 64) and a processor (42) to control the therapy delivery circuit; wherein the second pulse train includes more pulses per unit time than the first pulse train (Figs. 12 and 13); wherein the device defines pulses with amplitudes less than 10.5 volts and frequencies between 2 and 20 Hz, and is capable of pulse widths between 10 and 500 microseconds and pulse intervals of 10 to 500 milliseconds (Fig. 12, column 3, lines 36-46); wherein the device is capable of causing the fiber structure of the prostate gland to relax, given these programmed parameters.

Krakovsky'840 does not disclose that the time periods for the first and second pulse trains are on an order of a week. However, it would have been obvious to one of ordinary skill in the art at the time of the invention to use a training period on the order of a week, since it has been held that, where the general conditions of a claim are disclosed in the prior art, discovering an optimum value or range for a result effective variable involves only routine skill in the art.

It is noted that claim 28 and, by way of dependency, claim 29 invoke the means-plus-function language of 35 U.S.C. 12, 6th paragraph, where the means for generating and delivering a training sequence of stimulation pulses is taken to refer to the device described above comprising one or more leads, one or more pulse generators, and a processor control circuit.

It is noted that the functional language of the device claims does not distinguish the instant application over the Krakovsky'840 device because the earlier patented device is inherently capable of all the limitations contained in the instant claims.

12. Claims 1, 2, 5-11, 18, 30-32, 38 and 39 stand rejected under 35 U.S.C. 102(e) as anticipated by or Whitehurst'895, in the alternative, under 35 U.S.C. 103(a) as obvious over Whitehurst'895 in view of Whitehurst'294.

Regarding claims 1, 5 and 6, Whitehurst'895 discloses a method of delivering one or more therapeutic stimulation pulses via an implantable medical device to treat sexual dysfunction (TITLE; ABSTRACT); wherein the stimulation pulses treat dysfunction by causing erection and ejaculation (column 3, line 64 through column 4, line 6; column 6, lines 44-51).

Regarding claim 2, and further regarding claim 1, it is noted that Whitehurst'895 discloses stimulation of the nerves around the tissue of the prostate (column 1, lines 46-65; column 5, lines 20-38). However, it is commonly accepted in the medical art that stimulation of a muscle is in fact referring to the stimulation of the motor neurons effecting the muscle tissue, as such tissue in and of itself is not capable of producing a cause-and-effect relationship or providing for propagation of an electrical stimulation throughout an entire organ (such as the prostate) or across a significant distance without coincident stimulation of adjacent nerves. Therefore, a stimulation of the nerves proximally located to or affecting the prostate organ, both of which are disclosed in Whitehurst'895, signifies an inherent stimulation of the prostate tissue itself. Therefore, the limitation of the instant claims does not distinguish over the prior art.

Alternatively, in the same field of endeavor, Whitehurst'294 teaches direct electrical stimulation of the prostate to provide a minimally invasive means of reducing prostate volume (column 3, lines 55-68). Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the method of Whitehurst'895 to include direct electrical stimulation of the prostate gland as taught by Whitehurst'294 in order to provide the same benefit of reducing prostate volume with a minimally invasive process (motivation to combine provided by Whitehurst'294, column 3, lines 55-68).

Regarding claims 7-9, Whitehurst'895 discloses a method preventing ejaculation and premature ejaculation (column 5, lines 34-38; column 17, lines 15-20), given that inhibiting erection would serve to delay or inhibit ejaculation, and that it is stated that a user can turn off the device to return the user to a flaccid state (column 14, lines 66-67).

Regarding claim 10, Whitehurst'895 discloses using telemetry with a patient programmer (columns 14-15).

Regarding claim 11, Whitehurst'895 discloses using sensed physiological conditions (column 4, lines 42-52; column 12, line 64 through column 13, line 17)

Regarding claim 18, Whitehurst'895 discloses delivering drugs to the prostate in conjunction with delivering one or more therapeutic stimulation pulses (column 3, line 64 through column 4, line 30).

Regarding claims 30-32, 38 and 39, Whitehurst'895 discloses an implantable medical device that delivers stimulation pulses to the prostate gland (as outlined above) and an implantable drug pump programmed to deliver stimulation pulses and agents in

Art Unit: 3762

complementary fashion (column 3, line 63 through column 4, line 51; column 10, lines 60-65). It is noted that a recitation with respect to the manner in which a claimed apparatus is intended to be employed does not differentiate the claimed apparatus from a prior art apparatus satisfying the claimed structural limitations. *Ex parte Masham*, 2 USPQ2d 1647 (1987).

13. Claims 4 and 19-22, 24-25, 27 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Whitehurst'895 in view of Mann'171; or Whitehurst'895 in view of Whitehurst'294 as applied to claim 1 above, further in view of Mann'171 and still further in view of Krakovsky'840.

Regarding claims 4, 21 and 27, Whitehurst'895 or Whitehurst'895 in view of Whitehurst'294 discloses the method of the present invention substantially as claimed, but does not expressly disclose the parameter limitations of using pulse widths between 180 and 450 microseconds and voltage between 1 and 10 volts. In the same field of endeavor, Mann'171 teaches a pulse width range of 50-350 microseconds and a frequency range of 2-20 pulses per second (Hz) as being typical for electrical stimulation of male reproductive nerves (column 21, line 48 through column 22, line 14).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to employ these ranges for stimulation parameters in the method of the Whitehurst'895 or Whitehurst'895 in view of Whitehurst'294 to achieve the same advantage of successful and clinically safe control of male sexual function (motivation to combine provided by Mann'171, column 21, line 48 through column 22, line 14).

Art Unit: 3762

Regarding claims 19, 20, 22, 24, 25, 28, 29 and 33-37, Whitehurst'895 in view of Mann'171 or Whitehurst'895 in view of Whitehurst'294, f.i.v. Mann'171 discloses the method and device of the present invention substantially as claimed, but does not expressly disclose that the training sequence define a first and second pulse train, wherein the second pulse train includes more pulses per unit time than the first pulse train. In the same field of endeavor, Krakovsky'840 clearly shows in Figs. 12 and 13 a training sequence where a second, third and fourth, pulse sequence each includes more pulses per unit time than the previous sequence for the purpose of treating sexual dysfunction. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the system as disclosed by the combinations of Whitehurst'895, Whitehurst'294 and Mann'171 with a similar pulse sequence structure to provide the system with the same advantages of treating sexual dysfunction (motivation to combine provided by Figs. 12 and 13 of Krakovsky'840).

It is noted that Whitehurst'895 does not disclose that the time periods for the first and second pulse trains are on an order of a week. However, it would have been obvious to one of ordinary skill in the art at the time of the invention to use a training period on the order of a week, since it has been held that, where the general conditions of a claim are disclosed in the prior art, discovering an optimum value or range for a result effective variable involves only routine skill in the art.

Response to Arguments

14. Applicant's arguments, see paragraph 3 of page 8, filed 27 December 2006, with respect to the objection to claims 4-9 have been fully considered and are persuasive.

The objection to claims 4-9 has been withdrawn.

15. Applicant's arguments filed 27 December 2006 with regard to independent claim 1 have been fully considered but they are not persuasive.

16. Regarding independent claim 1, Applicant argues that none of the applied references discloses or suggests stimulation of tissue of the prostate gland specifically for treatment of sexual dysfunction (paragraph 3, page 9), and further that any conclusion of obviousness is wrong because benign prostatic hyperplasia (BPH) and sexual dysfunction are different disorders (line 1 of page 10), and still further that stimulation of nerves is not stimulation of prostate tissue regardless of the surrounding physiology.

In response to applicant's argument that stimulation of the prostatic tissue is not specifically disclosed for treatment of sexual dysfunction, the test for obviousness is not whether the features of a secondary reference may be bodily incorporated into the structure of the primary reference; nor is it that the claimed invention must be expressly suggested in any one or all of the references. Rather, the test is what the combined teachings of the references would have suggested to those of ordinary skill in the art. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981).

In response to applicant's argument that there is no suggestion to combine the references because BPH and sexual dysfunction are different disorders, the examiner

Art Unit: 3762

recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, the fact that BPH is different from sexual dysfunction does not negate the combinability of the references. It is noted that studies, e.g. those cited on the PTO-892 included herewith, have conclusively and intimately linked BPH and sexual dysfunctions, wherein proper treatment of BPH leads to improved sexual function (e.g. relief of erectile dysfunction) and worsening of the BPH condition contributes to deterioration of sexual faculty including decreased ejaculation volume (Schou et al.); decrease in libido (Carbone et al.); or retrograde ejaculation and discomfort. Therefore, it is considered to be well within the common knowledge of one skilled in the art to understand that a treatment of BPH also has positive effects in treating symptoms of sexual dysfunction which are exacerbated by the BPH condition.

In response to applicant's argument that stimulation of nerves is different from stimulation of prostate muscle tissue it is noted that a broad but reasonable interpretation of the claim language as written ("tissue of a prostate gland," claim 1, line 2) could include the nerve *tissue* that innervates the prostate, as the systems linked to a gland or organ can also reasonable be considered "a tissue of" that gland or organ, nor does a teaching of specific stimulation areas exclude a device from being capable of delivering stimulation to proximate, related tissues.

17. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

18. Applicant's arguments filed 27 December 2006 with regard to independent claims 19, 24, 28 and 33 have been fully considered but they are not persuasive.

The Examiner regrets that the rejections applied do not make sense to the Applicant. In considering the following, it is noted that claims 24 and 28 are directed to a *device*, whereas claims 19 and 33 are directed to a *method*. Therefore, the Krakovsky reference is sufficient to anticipate the *device* claims since the disclosed apparatus is capable of performing all intended functionality of the claimed invention and includes all of the structural limitations set forth in the instant device claims. For the method claims, the combination of Krakovsky and Whitehurst'294 provides a sound grounds of rejection (as explained in the preceding paragraphs) of the method claims as being obvious.

19. In response to Applicant's argument that Krakovsky includes additional structure in the form of an agent pump not required by Applicant's invention, it must be noted that Krakovsky discloses the invention as claimed. The fact that it discloses additional structure not claimed is irrelevant.

20. Regarding Applicant's argument that claims 19, 24, 28 and 33 are not concerned with treatment of sexual dysfunction but rather provide for training pulses to the prostate

Art Unit: 3762

gland for treatment of BHP, it is noted that the claims as written are not specific as to the pathology of the treated disease, and therefore the fact that the applied reference is for treatment of sexual dysfunction does not preclude the art from anticipating the claims.

21. Regarding Applicant's various arguments that Krakovsky and Whitehurst'294 fail to teach delivery of a training sequence of pulses, it is noted that such a training sequence is clearly and explicitly disclosed in the cited paragraphs and figures of Krakovsky as reiterated above for emphasis from the previous Office Actions.

Specifically looking at Figures 12 and 13 of Krakovsky, Examiner fails to comprehend how a pulse train or training sequence as claimed by Applicant can be reasonably distinguished from stimulation delivered at a first frequency delivered for a specific time immediately followed by stimulation of a second frequency for a second specific time as is clearly depicted, and which is very obviously different from an "individual stimulation" as conjectured in the last line of page 15 filed in Applicant's response. At the most rudimentary level, an "individual stimulation" could not possibly have a frequency variable attached to it, as it inherently takes more than one stimulation to determine the existence of frequency.

22. Regarding Applicant's argument that the bladder has no "nexus" with prostate stimulation, it is noted that the bladder and prostate share similar structure and corollary function within their respective physiological systems, and therefore provide a "nexus." Furthermore, it is not the type of tissue but rather the mode of therapy that is of interest in motivating a combination with the Mann reference.

Art Unit: 3762

23. Regarding Applicant's argument that the limitation of delivering stimulation over the period of a week does not constitute a results-effective variable, it has been firmly established in the case law that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges (*In re Aller*, 105 USPQ 233) or optimum value of a result effective variable (*In re Boesch*, 617 F.2d 272, 205 USPQ 215 (CCPA 1980)) involves only routine skill in the art.

24. Applicant's arguments filed 27 December 2006 with respect to claims 30 and 38 have been fully considered but they are not persuasive. It is noted that any manner of delivering both an agent and electrical stimulation can be considered complementary. Furthermore, the term complementary is not of sufficient scope to clearly define and limit the claim to exclude the manner of co-stimulation set forth in the applied prior art, alone or in combination.

Regarding Applicant's argument that the programming of the device as functional language inherently taught by Krakovsky, it is noted that if the prior art structure is capable of performing the intended use, then it meets the claim. As rewritten, claims 30 and 38 still fail to structurally distinguish over the prior art.

25. Applicant's arguments, see paragraph 2 of page 13, filed 27 December 2006, with respect to the rejection of claims 24, 25, 27-29 and 33-37 under 35 U.S.C. 103(a) as unpatentable over Whitehurst'294 alone have been fully considered and are persuasive. The §103 rejection of claims 24-25, 27-29 and 33-37 as unpatentable over Whitehurst'294 alone has been withdrawn.

Conclusion

1. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher A. Flory whose telephone number is (571) 272-6820. The examiner can normally be reached on M - F 8:30 a.m. to 5:00 p.m..


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela Sykes can be reached on (571) 272-4955. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3762

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christopher A. Flory

16 April 2007


George Manuel
Primary Examiner